Anti-Brucella IgM ELISA Kits

Posted by anna on February 26, 2022

Anti-Brucella IgM antibodies are a useful diagnostic tool for brucellosis. The results of an ELISA test can be used to detect human antibodies against the pathogenic Brucella ssp. in serum or plasma. This type of test is intended for research purposes only and cannot be used for clinical diagnosis. However, it is a useful diagnostic tool for patients who have suspected brucellosis.

In some cases, an ELISA kit is used to detect IgG-class antibodies to Brucella in blood or serum. In some cases, a patient may be positive or negative, depending on their clinical symptoms and possible risk factors. The IgG-class antibody to Brucella is produced by the immune system in response to an infection caused by Brucella. During a Brucellosis case, the IgG-class antibody should be elevated. This indicates that the patient may have been infected with brucella, which can cause gastrointestinal distress.

The ELISA test is the most commonly used for the diagnosis of brucellosis. It is useful for detecting a patient's IgG and IgM anti-Brucella antibodies. A patient with a positive IgM test may have a disease that does not produce an anti-Brucella IgG antibody. This makes the ELISA test a reliable diagnostic tool.

During a brucellosis infection, the immune system produces antibodies. The first is the IgM type, followed by the IgG and then IgA. If treatment is effective, the titer should drop. If the IgG and IgA titer are high, it means that the patient may develop a relapse or chronic focal disease. A titer of more than one isotypes may indicate a relapse or disease progression.

The CDC/Council of State and Territorial Epidemiologists has defined the criteria for a case of human brucellosis as an increase of four-fold or more in the immunofluorescence of the Brucella species in serum specimens. A positive ELISA result should be considered a false-positive and a new specimen should be obtained after 14 days to confirm a diagnosis of brucellosis.

The diagnosis of brucellosis is complicated because the IgG and IgM anti-Brucella tests do not always identify the cause of the disease. A patient with a positive IgM anti-Brucella test will be able to have the disease diagnosed correctly. This type of test can be used as a diagnostic tool to help physicians distinguish between people with the same symptoms and those with different conditions.


ELISA is used to detect Brucella antibodies in blood. It is helpful in confirming the diagnosis of brucella in single-positive patients. When the results of an ELISA test are negative, it can be difficult to distinguish between patients with different antibody levels. Nevertheless, Brucella antibodies are essential for the diagnosis of brucellosis. They help doctors differentiate between patients with the disease and identify the cause of the disease.


DRG ELISAs have become one of the most popular methods for testing Leptin levels in serum and plasma. The company's proprietary technology uses a sandwich principle to detect endogenous Leptin. The sample is incubated with a monoclonal antibody directed to the unique antigenic site of Leptin. Then, a biotinylated anti-Leptin antibody and a Steptavidin Peroxidase Enzyme Complex (SPEC) solution. The intensity of the colour is proportional to the concentration of Leptin in the sample.

DRG ELISAs are highly sensitive and reagent-free, allowing for rapid analysis of patient samples. These ELISAs can be used to detect antibodies against SARS-CoV-2 and Hepcidin 25 (bioactive) in the blood or saliva. They are also suitable for research in oncology, pediatrics, ophthalmology, immunology, pharmacology, physiology, and oncology.

DRG recently launched a new ELISA for Hepcidin, a type of hepatitis C virus, as part of their comprehensive panel. The Transferrin Receptor, or TfR, is a protein located on erythroid progenitor cells, which transports iron to the blood. The concentration of the soluble form of TfR in serum reflects the concentration of TfR in the cell.

DRG launched a soluble Transferrin Receptor ELISA, an additional addition to their existing broad ELISA panel. The TfR is a cellular protein that transports iron into cells. Soluble TfR in the serum reflects the presence of this cellular receptor. The ESRD has partnered with DIMA to develop the soluble TfR ELISA for the detection of iron in serum.

DRG is currently expanding its portfolio of ELISAs. The company recently unveiled its SARS-CoV-2 ELISA. Other ELISAs are based on a new technology called a microtiter plate. These products are often used in medical laboratories. The new ELISAs have multiple advantages and are designed to increase productivity. The company's product line is constantly evolving, and customers can always count on DRG to deliver a superior service.

DRG has been developing ELISAs since 1989 and is currently a leader in the field. Its portfolio of ELISAs includes total Ab, SARS-CoV-2 RBD ELISA, AMH, and Pancreatic Elastase ELISA. The company has also expanded its product line and is a member of the Association for Clinical Chemistry. DRG specializes in clinical laboratory testing, diagnostics, and related services.

DRG will exhibit at MEDICA 2013 in Hall 3 A69. The company has also published a new brochure on Alzheimer's disease and HYBRiD-XL for hemoglobin. The DRG HYBRiD-XL ELISA will meet the CE regulations in Europe. ADRs will be featured at SMTLSA and AACC in San Francisco. It will be a featured exhibit at MEDICA 2013.

DRG is a leader in the field of clinical laboratory tests. The company has expanded its portfolio to include a wide range of diagnostic services. Its patent-pending DRG-HYBRiD-XL is a new-generation hepcidin test kit that helps diagnose hemochromatosis and iron disorders. The DRG-HYBRiD-XA is available at MEDICA.


Copyright 2022 - 2022 by femyeah.com
Privacy Policy
We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.